-
Good news for family planning providers: Salary levels are reflecting a modest increase in 2004, according to the results of the annual Contraceptive Technology Update salary survey. The survey was mailed in July 2004 to 1,247 subscribers and had a response of 229, for a response rate of 18.36%.
-
-
Did the office telephone lines start buzzing when the media broadcasted reports of adverse events linked to use of the transdermal contraceptive Ortho Evra? Theres no doubt that clinicians have, since those reports, fielded many questions about the safety of the patch, which has been used by about 4 million women since its November 2001 approval by the Food and Drug Administration (FDA).
-
-
A new, and as of yet unpublished study, has raised increased concern about the relationship between rofecoxib (Vioxx), Mercks blockbuster COX-2 inhibitor, and cardiovascular events.
-
-
Survival benefits in the first year after acute MI, in patients 65 years or older, seem to differ according to specific ACE I prescribed.
-
Neck pain is common among the general population. Half of those patients who report this symptom have persistent complaints at 1 year. At particular risk for persistent neck pain are those ages 45-59 years, those with chronic low back pain, and patients who ride their bicycles regularly.
-
The diagnosis of hyperhidrosis, or excessive sweating, is achieved by clinical inquiry rather than laboratory testing, though quantitative metrics are available for clinical research.
-
The ECG in the Figure was obtained from a 23-year-old male who presented with a several day history of atypical chest pain. His ECG was interpreted as consistent with an early repolarization variant. Should anything else be considered in the differential?